April 15, 2008 – Pacira Pharmaceuticals, Inc. announced a collaboration with Amylin Pharmaceuticals, Inc. for the development of sustained release injectable products based on the DepoFoam® technology platform from Pacira. The companies will work together to enhance the dosing profile for compounds within Amylin’s early research and development pipeline. The goal of the collaboration is to develop multiple products based on sustained release, subcutaneous injection...
..."Pacira’s DepoFoam® technology is an attractive delivery system and Amylin is excited to apply this technology to our peptide and protein therapeutics platform," said Christopher Rhodes, Ph.D., Executive Director, Pharmaceutical Sciences of Amylin. “This collaboration fits well with Amylin’s research and development activities, which leverage our expertise in metabolism to develop potential therapies for diabetes and obesity.”... [PDF] Pacira Pharmaceuticals' Press Release -
